Roth Affirms Cytokinetics (CYTK) at 'Buy' Following Enrollment of First VIGOR-ALS Patient
Tweet Send to a Friend
Roth Capital affirms Cytokinetics (Nasdaq: CYTK) at Buy with a price target of $22 after the company announced the first ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
